自願性及業務進展公告 簽訂眼科藥物諾適得®與倍優適®經銷協議 China Medical System Holdings Limited（「本公司」，連同其附屬公司統稱為「本集 團」）欣然宣佈，於二零二五年十月二十七日，本集團通過本公司附屬公司與 Novartis Pharma Services AG （「諾華」）就雷珠單抗注射液（商品名：諾適得）（「諾 適得®」）、布西珠單抗注射液（商品名：倍優適）（「倍優適®」）簽訂經銷協議（「協議」）。 根據協議，本集團獲得產品在中華人民共和國（為協議之目的，不含香港特別行政區、 澳門特別行政區、台灣）（「區域」）的協議所約定之獨家進口、經銷、銷售、推廣權利； 諾華继续负责生產、供應產品。合作期限為协议约定的生效日起五年。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 諾適得® 諾適得®是重組抗血管內皮生長因子（VEGF）人源化單克隆抗體Fab片段，靶向抑制人血 管內皮生長因子A（VEGF-A），以抑制血管內皮細胞 ...

Novartis has agreed to buy Avidity Biosciences in a $12 billion biotech deal, the biggest acquisition for the Swiss drug maker in more than a decade. Joining us now is Bloomberg Intelligence is senior pharmaceutical analyst Sam Zell. Sam, thanks for joining us on the show.What does this deal tell us about potential M&A activity across the pharma space. Well, good morning to you. So this is by my count, we keep a tally of this.Of course, Bloomberg. This will be the 21st deal for 2025, where large pharma comp ...

Core Insights - Novartis has agreed to acquire Avidity Biosciences for $12 billion, marking its largest acquisition in over a decade [1] - This acquisition is part of a broader trend where large pharmaceutical companies are increasingly purchasing biotech firms, with this being the 21st such deal in 2025 [2][4] - The deal is strategically important for Novartis as it seeks to maintain growth momentum beyond 2029, particularly after a significant drug's patent expiration [2][3] Industry Trends - The recent surge in mergers and acquisitions (M&A) activity in the biotech sector indicates a growing confidence among large pharma companies, driven by a more stable regulatory environment [5][6] - The focus on rare disease assets in this deal suggests that these drugs face less scrutiny regarding pricing and regulation compared to standard drugs, potentially mitigating risks associated with pricing pressures [6][7] - The increase in M&A activity is also linked to a reprieve from certain tariff threats, which has provided companies with the confidence to pursue acquisitions [5][6]

Shares of Avidity Biosciences Inc (NASDAQ:RNA) rose sharply in pre-market trading after the company agreed to be acquired by Novartis AG (NYSE:NVS).Holders of Avidity common stock will receive $72.00 per share in cash at closing, representing a premium of around 46% over Avidity’s closing share price on Oct. 24.Avidity Biosciences shares surged 42.1% to $69.85 in the pre-market trading session.Here are some other stocks moving in pre-market trading.GainersClick Holdings Limited (NASDAQ:CLIK) gained 173% to ...

Core Viewpoint - Novartis AG is preparing to release its third-quarter 2025 earnings, with market expectations indicating a solid financial performance in terms of earnings per share and revenue [1][2]. Financial Performance Expectations - Wall Street anticipates Novartis to report earnings per share (EPS) of $2.26, while analysts project a slightly higher EPS of $2.28 [2][6]. - The revenue forecast is approximately $13.87 billion, with analysts estimating a close $13.7 billion [2][6]. Stock Performance and Valuation - Novartis' stock opened at $130.48, with a market capitalization of $275.64 billion [3]. - The stock has a price-to-earnings (P/E) ratio of 18.99, indicating investor willingness to pay for earnings [3][6]. - The beta of 0.64 suggests moderate volatility compared to the market, indicating less likelihood of large price swings [3][6]. Financial Health Metrics - The current ratio is 0.82 and the quick ratio is 0.62, reflecting the company's ability to cover short-term liabilities [4]. - The debt-to-equity ratio of 0.53 shows a balanced approach to financing, with moderate debt levels compared to equity [4]. Moving Averages and Trends - The stock's fifty-day simple moving average is $127.56, while the 200-day average is $119.49, indicating a positive trend over the past year [4]. Valuation Metrics - Novartis has a price-to-sales ratio of 4.64 and an enterprise value to sales ratio of 5.11, reflecting the market's view of its revenue and total worth [5]. - The enterprise value to operating cash flow ratio is 13.44, highlighting the company's cash flow efficiency [5]. - An earnings yield of 3.79% provides insight into the return on investment for shareholders [5].

Core Insights - Novartis has signed a strategic cooperation agreement with Kangzhe Weisheng, a wholly-owned subsidiary of Kangzhe Pharmaceutical, for the exclusive import, commercial promotion, and distribution rights of two ophthalmic products in China starting from November 1, 2025 [1] - The agreement is set for a duration of five years, indicating a long-term partnership between the companies [1] - This strategic agreement aligns with Novartis' global "focus" strategy, concentrating on four core therapeutic areas: cardiovascular, renal and metabolic, oncology, and immunology and neuroscience [1] Company Summary - Novartis will transfer the rights for its ophthalmic products, Nofiz (Ranibizumab injection) and Beiyoushi (Brolucizumab injection), to Kangzhe Weisheng [1] - The partnership aims to enhance resource integration and provide innovative drugs with high clinical value to patients [1]

Group 1 - Novartis has been actively pursuing acquisition deals over the past year to strengthen its pipeline in response to patent expirations of key drugs like heart failure therapy, Kymriah [1][2] - On October 26, Novartis announced a proposed cash acquisition of Avidity Biosciences for approximately $12 billion to enhance its treatment portfolio for rare muscle diseases [1] - Avidity's latest market capitalization is close to $6.7 billion, and Novartis has completed nearly $20 billion in potential acquisition deals over the past year [1] Group 2 - Recent acquisitions by Novartis include: - $1.1 billion for gene therapy company Kate Therapeutics in November last year [2] - $3.1 billion for Anthos Therapeutics to enhance its cardiovascular treatment line in February [2] - $1.7 billion for Regulus Therapeutics for a kidney disease therapy in April [2] - Up to $1 billion agreement with Matchpoint Therapeutics for oral drugs targeting inflammatory diseases in July [2] - $1.4 billion acquisition of Tourmaline Bio for a cardiovascular treatment drug in September [2] - These acquisitions are aimed at addressing the patent expiration crisis of key drugs, with Novartis's stock price increasing approximately 34% this year, leading to a market capitalization exceeding $275 billion [2]

Group 1 - The eighth China International Import Expo (CIIE) is set to open, with Novartis participating for the eighth consecutive time, emphasizing its commitment to being a valuable and trustworthy healthcare partner in China [1][2] - Novartis will showcase nearly 20 innovative products across four core therapeutic areas: cardiovascular, renal and metabolic, oncology, and neuroscience, highlighting its strong innovation capabilities [1] - The "Focus on Innovation" exhibition area will feature award-winning products and immersive experiences, allowing attendees to engage with cutting-edge drug mechanisms and treatment methods [1] Group 2 - Novartis aims to deepen its roots in China, reflecting on its century-long history in the country and its new vision for development since 2018, which includes increased investment and collaboration with local industries [2] - The "Access to Medicine" exhibition area will demonstrate Novartis's efforts to enhance medicine accessibility for Chinese patients through partnerships with government, hospitals, and industry players [2] - A giant curved screen at the Novartis booth will showcase advanced pharmaceutical technologies, while an employer culture experience area will allow visitors to engage with the company's culture and receive commemorative badges [2]

Core Viewpoint - Novartis has agreed to acquire Avidity Biosciences for $72 per share in cash, representing a 46% premium, with a total transaction value of $12 billion. This acquisition is expected to stimulate further mergers and acquisitions in the pharmaceutical industry [1] Group 1 - The acquisition price of $72 per share indicates a significant premium of 46% over Avidity's current market value [1] - The total value of the transaction is estimated at $12 billion, highlighting the scale of the deal within the biotech sector [1] - Avidity is developing experimental drugs for rare diseases, including treatments for neuromuscular diseases, which aligns with Novartis's strategic focus on innovative therapies [1]

Core Viewpoint - Novartis has announced an agreement to acquire Avidity Biosciences for $12 billion, focusing on innovative RNA therapies for neuromuscular diseases [3][30]. Group 1: Acquisition Details - The acquisition involves Novartis purchasing all outstanding shares of Avidity at $72.00 per share, representing a 46% premium over Avidity's closing price on October 24, 2025 [30]. - The deal is expected to close in the first half of 2026, contingent upon the separation of Avidity's early precision cardiology projects into a new entity, SpinCo [35]. - Avidity's late-stage neuroscience projects will be integrated into Novartis, enhancing its pipeline in treating genetic neuromuscular diseases [8][22]. Group 2: Strategic Importance - The acquisition is projected to increase Novartis's expected compound annual growth rate (CAGR) from 5% to 6% for the years 2024-2029, presenting a significant opportunity for shareholder returns [13][30]. - Avidity's innovative AOC RNA therapy platform aims to address severe genetic neuromuscular diseases, potentially leading to first-in-class treatment candidates [8][22]. Group 3: Market Potential - External forecasts suggest multi-billion-dollar peak sales potential for Avidity's therapies targeting diseases such as DM1 and FSHD, with no loss of exclusivity expected before 2042 [26][30]. - Avidity's therapies are designed to correct underlying genetic causes, offering meaningful benefits to patients suffering from conditions like DM1, FSHD, and DMD [22][47]. Group 4: Clinical Development - Avidity's lead candidate, Del-desiran, is designed to degrade DMPK mRNA to address the root cause of DM1, with promising data from Phase 1/2 studies indicating potential for significant clinical impact [36][40]. - Del-brax, targeting FSHD, has shown improvements in functional mobility and muscle strength in clinical trials, with ongoing studies expected to yield further data [48][50].